vs
Side-by-side financial comparison of ADMA BIOLOGICS, INC. (ADMA) and Forestar Group Inc. (FOR). Click either name above to swap in a different company.
Forestar Group Inc. is the larger business by last-quarter revenue ($273.0M vs $139.2M, roughly 2.0× ADMA BIOLOGICS, INC.). ADMA BIOLOGICS, INC. runs the higher net margin — 35.5% vs 5.6%, a 29.8% gap on every dollar of revenue. On growth, ADMA BIOLOGICS, INC. posted the faster year-over-year revenue change (18.4% vs 9.0%). ADMA BIOLOGICS, INC. produced more free cash flow last quarter ($34.6M vs $-157.1M). Over the past eight quarters, ADMA BIOLOGICS, INC.'s revenue compounded faster (30.4% CAGR vs -9.6%).
ADMA Biologics Inc. is a biopharmaceutical enterprise focused on the research, development, manufacturing and commercialization of specialty plasma-derived immunoglobulin therapies. It primarily operates in the United States, catering to patients with primary immunodeficiency and other immune-related disorders, healthcare providers and medical institutions across its core immune health therapeutic segment.
Forestar Group Inc. is a residential lot development company based in Arlington, Texas. The company has operations in 51 markets in 21 states and delivered 11,518 residential lots during the twelve-month period ended December 31, 2020. The company is publicly traded on the New York Stock Exchange and in October 2017 became a majority-owned subsidiary of D.R. Horton, Inc., the largest homebuilder by volume in the United States since 2002. The company primarily acquires entitled real estate and...
ADMA vs FOR — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $139.2M | $273.0M |
| Net Profit | $49.4M | $15.4M |
| Gross Margin | 63.8% | 20.1% |
| Operating Margin | 45.1% | 7.6% |
| Net Margin | 35.5% | 5.6% |
| Revenue YoY | 18.4% | 9.0% |
| Net Profit YoY | -55.9% | -6.7% |
| EPS (diluted) | $0.20 | $0.30 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $139.2M | $273.0M | ||
| Q3 25 | $134.2M | $670.5M | ||
| Q2 25 | $122.0M | $390.5M | ||
| Q1 25 | $114.8M | $351.0M | ||
| Q4 24 | $117.5M | $250.4M | ||
| Q3 24 | $119.8M | $551.3M | ||
| Q2 24 | $107.2M | $318.4M | ||
| Q1 24 | $81.9M | $333.8M |
| Q4 25 | $49.4M | $15.4M | ||
| Q3 25 | $36.4M | $86.9M | ||
| Q2 25 | $34.2M | $32.9M | ||
| Q1 25 | $26.9M | $31.6M | ||
| Q4 24 | $111.9M | $16.5M | ||
| Q3 24 | $35.9M | $81.5M | ||
| Q2 24 | $32.1M | $38.7M | ||
| Q1 24 | $17.8M | $45.0M |
| Q4 25 | 63.8% | 20.1% | ||
| Q3 25 | 56.3% | 22.3% | ||
| Q2 25 | 55.1% | 20.4% | ||
| Q1 25 | 53.2% | 22.6% | ||
| Q4 24 | 53.9% | 22.0% | ||
| Q3 24 | 49.8% | 23.9% | ||
| Q2 24 | 53.6% | 22.5% | ||
| Q1 24 | 47.8% | 24.9% |
| Q4 25 | 45.1% | 7.6% | ||
| Q3 25 | 38.0% | 16.9% | ||
| Q2 25 | 35.1% | 11.2% | ||
| Q1 25 | 30.4% | 11.6% | ||
| Q4 24 | 32.6% | 8.7% | ||
| Q3 24 | 33.1% | 19.7% | ||
| Q2 24 | 36.6% | 16.2% | ||
| Q1 24 | 26.7% | 17.6% |
| Q4 25 | 35.5% | 5.6% | ||
| Q3 25 | 27.1% | 13.0% | ||
| Q2 25 | 28.1% | 8.4% | ||
| Q1 25 | 23.4% | 9.0% | ||
| Q4 24 | 95.2% | 6.6% | ||
| Q3 24 | 30.0% | 14.8% | ||
| Q2 24 | 29.9% | 12.2% | ||
| Q1 24 | 21.7% | 13.5% |
| Q4 25 | $0.20 | $0.30 | ||
| Q3 25 | $0.15 | $1.70 | ||
| Q2 25 | $0.14 | $0.65 | ||
| Q1 25 | $0.11 | $0.62 | ||
| Q4 24 | $0.45 | $0.32 | ||
| Q3 24 | $0.15 | $1.59 | ||
| Q2 24 | $0.13 | $0.76 | ||
| Q1 24 | $0.08 | $0.89 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $87.6M | $211.7M |
| Total DebtLower is stronger | $72.1M | $793.2M |
| Stockholders' EquityBook value | $477.3M | $1.8B |
| Total Assets | $624.2M | $3.2B |
| Debt / EquityLower = less leverage | 0.15× | 0.44× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $87.6M | $211.7M | ||
| Q3 25 | $61.4M | $379.2M | ||
| Q2 25 | $90.3M | $189.2M | ||
| Q1 25 | $71.6M | $174.3M | ||
| Q4 24 | $103.1M | $132.0M | ||
| Q3 24 | $86.7M | $481.2M | ||
| Q2 24 | $88.2M | $359.2M | ||
| Q1 24 | $45.3M | $416.2M |
| Q4 25 | $72.1M | $793.2M | ||
| Q3 25 | $72.4M | $802.7M | ||
| Q2 25 | — | $872.8M | ||
| Q1 25 | — | $872.5M | ||
| Q4 24 | $72.3M | $806.8M | ||
| Q3 24 | — | $706.4M | ||
| Q2 24 | — | $706.1M | ||
| Q1 24 | — | $705.7M |
| Q4 25 | $477.3M | $1.8B | ||
| Q3 25 | $431.2M | $1.8B | ||
| Q2 25 | $398.3M | $1.7B | ||
| Q1 25 | $373.4M | $1.6B | ||
| Q4 24 | $349.0M | $1.6B | ||
| Q3 24 | $231.9M | $1.6B | ||
| Q2 24 | $188.3M | $1.5B | ||
| Q1 24 | $153.7M | $1.5B |
| Q4 25 | $624.2M | $3.2B | ||
| Q3 25 | $568.7M | $3.1B | ||
| Q2 25 | $558.4M | $3.1B | ||
| Q1 25 | $510.6M | $3.0B | ||
| Q4 24 | $488.7M | $3.0B | ||
| Q3 24 | $390.6M | $2.8B | ||
| Q2 24 | $376.4M | $2.7B | ||
| Q1 24 | $350.9M | $2.6B |
| Q4 25 | 0.15× | 0.44× | ||
| Q3 25 | 0.17× | 0.45× | ||
| Q2 25 | — | 0.52× | ||
| Q1 25 | — | 0.53× | ||
| Q4 24 | 0.21× | 0.50× | ||
| Q3 24 | — | 0.44× | ||
| Q2 24 | — | 0.47× | ||
| Q1 24 | — | 0.48× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $35.6M | $-157.0M |
| Free Cash FlowOCF − Capex | $34.6M | $-157.1M |
| FCF MarginFCF / Revenue | 24.8% | -57.5% |
| Capex IntensityCapex / Revenue | 0.8% | 0.0% |
| Cash ConversionOCF / Net Profit | 0.72× | -10.19× |
| TTM Free Cash FlowTrailing 4 quarters | $27.8M | $93.0M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $35.6M | $-157.0M | ||
| Q3 25 | $13.3M | $256.3M | ||
| Q2 25 | $21.1M | $15.8M | ||
| Q1 25 | $-19.7M | $-19.8M | ||
| Q4 24 | $50.2M | $-450.0M | ||
| Q3 24 | $25.0M | $119.2M | ||
| Q2 24 | $45.6M | $-61.7M | ||
| Q1 24 | $-2.2M | $-59.2M |
| Q4 25 | $34.6M | $-157.1M | ||
| Q3 25 | $-1.1M | $255.6M | ||
| Q2 25 | $18.7M | $15.0M | ||
| Q1 25 | $-24.4M | $-20.5M | ||
| Q4 24 | $47.5M | — | ||
| Q3 24 | $24.0M | $118.4M | ||
| Q2 24 | $43.6M | $-62.3M | ||
| Q1 24 | $-4.6M | $-59.8M |
| Q4 25 | 24.8% | -57.5% | ||
| Q3 25 | -0.8% | 38.1% | ||
| Q2 25 | 15.3% | 3.8% | ||
| Q1 25 | -21.2% | -5.8% | ||
| Q4 24 | 40.4% | — | ||
| Q3 24 | 20.0% | 21.5% | ||
| Q2 24 | 40.7% | -19.6% | ||
| Q1 24 | -5.6% | -17.9% |
| Q4 25 | 0.8% | 0.0% | ||
| Q3 25 | 10.7% | 0.1% | ||
| Q2 25 | 2.0% | 0.2% | ||
| Q1 25 | 4.1% | 0.2% | ||
| Q4 24 | 2.3% | 0.0% | ||
| Q3 24 | 0.9% | 0.1% | ||
| Q2 24 | 1.9% | 0.2% | ||
| Q1 24 | 2.9% | 0.2% |
| Q4 25 | 0.72× | -10.19× | ||
| Q3 25 | 0.36× | 2.95× | ||
| Q2 25 | 0.62× | 0.48× | ||
| Q1 25 | -0.73× | -0.63× | ||
| Q4 24 | 0.45× | -27.27× | ||
| Q3 24 | 0.70× | 1.46× | ||
| Q2 24 | 1.42× | -1.59× | ||
| Q1 24 | -0.12× | -1.32× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ADMA
| ADMA Bio Manufacturing Segment | $123.1M | 88% |
| Other | $16.0M | 12% |
FOR
| D.R.Horton Inc. | $183.8M | 67% |
| Other | $89.2M | 33% |
